November 2017—Beckman Coulter Life Sciences has introduced DuraClone RE antibody panels for the detection of rare, abnormal events in blood disorders. The panels provide tools to study low frequency populations of abnormal CD5+ B cells (RE CLB), abnormal plasma cells (RE PC), or abnormal B progenitor cells (RE ALB).
The three standardized, preformulated DuraClone RE kits, for research use only, deliver high sensitivity for rare cell populations and are able to accommodate either large sample volumes or high cellular concentrations. Using dry, unitized antibody combinations help preserve the strict assay conditions essential for reliable, reproducible rare event analysis.
The panels aim to eliminate errors from manual antibody pipetting, streamline workflow, improve turnaround time, and simplify inventory management. They are available in a 25-test package with three complete compensation kits specific for each panel.
Beckman Coulter Life Sciences, 800-742-2345